SecBot SecBot
PRESS-RELEASE ·Filed May 12, 2026

PHVS

Pharvaris N.V.
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The stock will trade on CHAPTER-3 data timing (3Q2026) and NDA submission progress (1H2026). The $132M raise removes near-term dilution risk but signals capital needs. Monitor for any pre-announcement or regulatory updates on the NDA filing.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$32.94
T+0 close · May 12, 2026 · via day close
Latest settled
+5.98%
T+60 · $34.91
Vs SPY
+1.54%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $32.94entry
  2. T+1 · 6mo ago 0.00%α +0.00% · $32.94
  3. T+5 · 6mo ago −12.11%α −10.95% · $28.95
  4. T+20 · 5mo ago −2.25%α −1.63% · $32.20
  5. T+60 · 3mo ago +5.98%α +1.54% · $34.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a $132M offering into 2028. The key catalysts are the CHAPTER-3 Phase 3 HAE prophylaxis data due in 3Q2026 and the NDA submission for deucrictibant IR in 1H2026.

Key Financial Metrics

EPS
−$0.59
est −$0.71 · +16.9%
Rating
in line

Key Facts

  • Q1 2026 loss per share €-0.59 vs €-0.85 YoY (IFRS basis)
  • Cash and equivalents €247M as of March 31, 2026, down from €292M at Dec 31, 2025
  • Closed $132.3M underwritten offering post-quarter, extending cash runway into 2028
  • CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q2026
  • NDA submission for deucrictibant IR on track for 1H2026
  • R&D expenses €29.9M (Q1 2026) vs €30.9M (Q1 2025); G&A €14.0M vs €11.3M
  • No revenue reported; pre-revenue biotech

Financial Impact

No revenue; operating loss €43.9M (R&D + G&A) vs €42.2M YoY. Cash burn rate ~€45M/quarter, extended by $132M offering.

cashoperating expensesloss per share

Risk Factors

  • CHAPTER-3 Phase 3 failure would significantly impair pipeline value
  • Regulatory delays or rejection of deucrictibant IR NDA
  • Cash runway depends on no major cost overruns; further dilution possible if milestones slip
  • Competition from existing HAE therapies (Takhzyro, Orladeyo, Kalbitor)

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293384

Track record

51 reports on PHVS

Performance horizon

15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
  3. Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  4. Nov 12, 20264d ago 6-K Neutral 4/10 No price data
  5. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
  6. Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
  7. Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  8. Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
  9. Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
  10. Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
Showing 10 of 51

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026